Summary of research on curcumin and leukemia.
From the document.
https://www.researchgate.net/publication/324650356_Molecular_Targets_of_Curcumin_and_Future_Therapeutic_Role_in_Leukemia
Summary of research: What role might curcumin play in leukemia?
1. What does this research study?
This article is a review summarizing research on curcumin—a key compound found in turmeric (*Curcuma longa*)—and investigating how it might affect cancer cells, specifically leukemia cells.
The researchers focused particularly on curcumin's ability to influence various intracellular signaling pathways and proteins involved in the growth, division, and death of cancer cells.
2. Why is curcumin attracting interest?
Curcumin is a polyphenol found in turmeric that possesses several biological properties, such as:
Anti-inflammatory activity
Antioxidant activity
The ability to influence cell growth
The ability to trigger cell death in certain types of cells
The ability to disrupt signaling pathways associated with cancer cells
The article discusses numerous studies showing that curcumin can inhibit cancer cell proliferation and induce apoptosis—or "programmed cell death"—in certain types of cancer cells.
3. So, what might curcumin do to cancer cells?
To put it simply:
Normal cells → Have a balanced system controlling growth and death. But...
Cancer cells → Control systems are unbalanced → Excessive division → Failure to die → Continuous proliferation.
Based on the research compiled in the article... It has been found that curcumin can impact multiple points within these systems, such as:
Curcumin
↓
Interfering with signals that promote cancer cell growth
↓
Halting cell division
↓
Inducing apoptosis
↓
Reducing the number of cancer cells
The article highlights several key pathways, such as AKT, NF-κB, ROS, FLT3, MAPK, and JAK/STAT.
4. Key mechanism discussed: The AKT Pathway
AKT is an intracellular signaling system that promotes cell growth and survival. In cancer cells, this system can become hyperactive, driving continued cancer cell growth.
Studies reviewed in the article indicate that curcumin can interfere with the PI3K/AKT pathway and is associated with the activation of p53, as well as apoptosis-related proteins like Bcl-2 and Bax.
Simply put: Curcumin may help "switch off signals that tell cancer cells to survive and divide."
5. ROS — Reactive Oxygen Species and cancer cells
This point is particularly interesting because curcumin’s interaction with ROS can vary depending on the cell type and the conditions within the cancer cell. Some research shows that curcumin can increase ROS levels within cancer cells, leading to heightened oxidative stress, which may trigger the following:
Increased ROS
↓
Intracellular damage
↓
Mitochondrial dysfunction
↓
Caspase activation
↓
Apoptosis
↓
Cancer cell death
The article reports this mechanism in certain types of leukemia cells; therefore, one should not simply conclude that "curcumin only eliminates free radicals," because in the context of cancer cells... Research reviewed in the article indicates that curcumin can also increase ROS levels within cancer cells to trigger cell death.
6. NF-κB — A key factor in inflammation and cancer
NF-κB is a gene regulatory system involved in various processes, such as:
Inflammation
Cell survival
Cell growth
Response to various signals
The article states that curcumin can inhibit NF-κB activity and downregulate specific genes or proteins associated with inflammation, survival, and the proliferation of cancer cells.
Simply put:
NF-κB acts like a "control switch" for various cellular processes, and research shows that curcumin can interfere with this switch.
7. FLT3 — Linked to Acute Myeloid Leukemia (AML)
Another target highlighted in the article is FLT3.
FLT3 is a receptor involved in signaling for cell growth and division; the article notes that FLT3 mutations or abnormal overexpression occur in some AML patients.
Dysfunction in the FLT3 system can activate pathways such as:
PI3K → AKT
MAPK
JAK/STAT
...all of which are associated with cancer cell growth.
Research reviewed in the article shows that curcumin can reduce FLT3 levels and is linked to cell cycle arrest as well as the induction of apoptosis in certain experimental models.
8. So, how does curcumin cause cancer cell death?
The primary mechanism discussed in the article is apoptosis.
Apoptosis is the process by which a cell systematically "instructs itself to die." A simple comparison:
Cancer cells = a car with a broken braking system that keeps moving forward.
Curcumin may interact with various systems governing acceleration and braking, causing cells to stop dividing and—in some experiments—triggering programmed cell death (apoptosis).
The article concludes that Curcumin can influence multiple pathways simultaneously—such as AKT, ROS, NF-κB, ERK, and FLT3—potentially leading to cell cycle arrest and apoptosis.
9. How does Curcumin affect normal cells?
The article discusses the Nrf2 mechanism, which is involved in the cell's antioxidant defense system.
Activating Nrf2 can boost the production of intracellular defenses against oxidative stress; thus, the article suggests that Curcumin may play a role in protecting normal cells from certain forms of oxidative stress.
However, one should be cautious about interpreting this to mean that Curcumin "kills only cancer cells without harming normal cells," as the article's statements summarize experimental evidence and do not imply that the same results will occur in every patient.
10. Have there been human trials?
Some clinical studies are mentioned, but the article primarily focuses on evidence from cellular and animal studies (preclinical research).
One example cited in the article involves administering turmeric powder alongside Imatinib to CML patients for six weeks, which resulted in reduced blood NOx levels; the authors suggest that Curcumin may have potential as an adjunct therapy.
However, this point should not be interpreted to mean that Curcumin has been proven capable of treating CML (chronic myeloid leukemia).
11. A major issue with Curcumin is its "poor absorption by the body."
This is a crucial point highlighted in the document.
Although Curcumin shows promising results in experimental settings, the body's ability to absorb it after oral ingestion is quite limited.
The article therefore discusses strategies to enhance bioavailability, such as:
Using Piperine
Using Liposomes
Encapsulation
Nanocarriers
Developing new Curcumin formulations or derivatives
This is a key reason why laboratory results cannot be directly equated to the effects of consuming standard Curcumin in humans.
12. Dosages mentioned in the article
The article notes that some Phase 1 clinical trials found humans could tolerate Curcumin dosages of 3,600–8,000 mg/day for a certain period, though adverse effects like diarrhea and nausea were observed in some cases.
However, these figures should not be taken as personal dosage recommendations.
This is because the dosages used in clinical trials differ from appropriate dosages for dietary supplements; the latter depend on the product formulation, absorption method, individual health status, and concurrent medication use.
13. Precautions noted in the article
A table in the article outlines several precautions, such as:
High doses may cause gastrointestinal symptoms.
Nausea, vomiting, or irritation may occur.
Allergic reactions may occur in some individuals.
Individuals with bleeding disorders should exercise caution.
Use should be discontinued prior to surgery.
Individuals with gallbladder obstruction should avoid it.
It may interact with other medications. Absorption into the bloodstream poses a significant limitation.
14. Summary of key points in a single diagram
This research can be visualized through the following simple diagram:
Curcumin from turmeric
↓
Affects multiple intracellular systems
↓
PI3K/AKT → Reduces survival/growth signaling
NF-κB → Reduces inflammation- and survival-related signaling
FLT3 → Reduces AML-related signaling
ROS → Increases oxidative stress in certain cancer cell types
ERK/JNK → Disrupts growth signaling
p53 / Caspase → Promotes apoptosis
↓
Halts cell division
↓
Induces cancer cell death in experimental settings
↓
May reduce cancer cell proliferation
These mechanisms explain why researchers are interested in Curcumin as a promising candidate for further cancer research.
15. What “this research indicates” vs. what “cannot yet be concluded”
What the evidence supports
Curcumin possesses diverse biological activities.
It affects multiple cancer-related pathways.
It halts the division of certain cancer cell types in experiments.
It can induce apoptosis in certain cancer cell types.
FLT3, AKT, NF-κB, and ROS are promising targets.
It holds potential for further development.
What cannot yet be concluded
It does not prove that turmeric cures cancer.
It does not prove that it is a cancer treatment drug.
Experimental cell results do not equate to clinical outcomes in patients.
An appropriate therapeutic dosage for cancer has not yet been determined.
Further clinical trials are required. Drug interactions and methods to enhance absorption require further study.
The authors conclude that additional clinical trials are necessary to determine appropriate dosages, administration methods, suitable target conditions, and interactions with other drugs before its therapeutic role can be clearly evaluated.
Source: